Skip to main content
our twitterour facebook page

OTCQB:  ODYY - Odyssey Group International, Inc.

Odyssey is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity.
Company Website:

The Winning Catalyst-
ODYY has entered into an agreement with NYSE: OGEN 
Read the Press Release below:

LAS VEGAS, NV / ACCESSWIRE / October 18, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products is providing an update on its Asset Purchase Agreement with Oragenics, Inc. (NYSE: OGEN).

When the Asset Purchase Agreement is consummated, Odyssey will receive eight (8) million shares of Oragenics Series F Convertible Preferred Stock at the close of the transaction. Oragenics has approximately 2.5 million shares of common stock outstanding. The preferred stock converts to Oragenics common stock on a one-to-one basis. In addition, Odyssey will receive $1 million in cash, of which $500,000 was paid on signing and $500,000 will be paid on the sooner of ninety days from the October 4, 2023, signing of the agreement, or on the successful proxy vote of the Odyssey stockholders.

The Company believes that asset sale is in the best interest of stockholders and provides many benefits. The 8 million shares of Series F Preferred Stock will become an asset of Odyssey. Oragenics has the resources and cash, as well as the ability to raise additional capital to fund the development of the platform technology and begin the clinical trials for the concussion drug.

"We are excited to be teaming with Oragenics to further the development and clinical trials of our novel neurological drug and drug delivery technologies. Oragenics has significant experience with nasal delivery and provides excellent synergy with our nasal drug delivery technology. Oragenics, Inc. trades on the New York Stock Exchange under the symbol: OGEN and the preferred shares, will provide tremendous stockholder value in the future," commented Michael Redmond, CEO of Odyssey.

The transaction is expected to close in the fourth quarter of 2023, subject to the satisfaction of various closing conditions, including approval of the transaction by Odyssey's shareholders and approval of the conversion of the Series F Preferred Stock by Oragenics shareholders.

Odyssey will retain its other assets and operations, including the CardioMap heart monitoring technology and the Save a Life choking rescue device. Both devices are currently in development and hold great promise for the future of the company. Once the Asset Purchase Agreement closes, Odyssey will also have the 8 million shares of Oragenics preferred stock.

What does this mean?

This transaction / sale, though previously announced,  has gone unseen by most retail investors.  The shareholder vote to approve this transaction takes place on or before December 7, 2023.  Once the transaction is complete,  the assets of ODYY will skyrocket and the book value of the company should end up around .80 per share.   At the current share price of .105 this stock is a steal.  

The company could issue a dividend of shares of OGEN to the shareholders that own ODYY.   If this occurs the shareholders of ODYY will get a huge windfall.  This fact makes buying shares of ODYY low risk in our opinion.

If the company does not issue a dividend of the payoff and keep the shares in order to raise capital to expand operations it is a huge win for shareholders as well.  

A third scenario could be that ODYY, having 75% ownership of OGEN, would simply merge with OGEN and take over controlling interest of the company.   This is a win for shareholders as well. 

Regardless of how you slice it,  shareholders of ODYY are in a great position and have a low downside risk in our opinion. 



Outstanding Shares-  82,429,061

Held at DTC-  36,243,957

Float-  35,266,944

Data from Otc Markets 
December 2023

Meet the CEO

J. Michael Redmond

Mr. Redmond has over 35 years commercial experience in medical device companies. Mr. Redmond held various sales and marketing positions at Abbott Laboratories, a multi-billion-dollar healthcare company. Mr. Redmond then went on to become the Director of Marketing and Business Development at KMC Systems Inc., now a leading private label developer and manufacturer of medical devices and instrumentation. Mr. Redmond helped grow the company from early stage to over $50M in revenue. KMC was sold to Elbit systems. Mr. Redmond then joined Bioject Inc as its VP of Sales and Marketing. Bioject was a medical device company specializing in unique drug delivery technologies. Mr. Redmond helped raise over $15M in capital, entered several licensing and distribution deals with major biotech and pharmaceutical companies growing the market cap of the company from under $10M to over $400M. Mr. Redmond has been CEO of Odyssey Health, Inc. since 2018.


Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion

LAS VEGAS, NV / ACCESSWIRE / November 16, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, has selected Syneos Health®, a leading fully integrated biopharmaceutical solutions organization to support its Investigational New Drug (IND) Application. Odyssey Health is developing a pharmaceutical treatment for mild Traumatic Brain Injury (mTBI), aka concussion.

Odyssey Health's lead drug candidate for concussion, ONP-002 has completed a Phase I safety trial in Australia. Odyssey submitted a pre-IND application to the FDA this summer and received instructive feedback in September. In preparation for IND submission and clinical trials in the US, Odyssey chose Syneos Health for guidance and review of all pre-clinical and clinical data needed for the final IND package and support of the clinical design protocol for the Phase II clinical trial to be conducted in the US. Syneos Health's expertise combined with the Company's familiarity with the drug candidate and nasal delivery technology further helps position the study for success.

Along with other fully integrated biopharmaceutical solution services, Syneos Health brings global regulatory affairs solutions (GRAS), providing end-to-end regulatory support across many indications and regions. The Syneos Health GRAS team will support Odyssey with a regulatory review for the clinical development plans for Odyssey's concussion drug, ONP-002 and novel intranasal device. As a class II drug: device combination Syneos Health will assist Odyssey in getting the needed advice for Phase II/III clinical trial design and implementation from the FDA.

"Odyssey is excited to partner with such a respected group of experts. Syneos Health has been a global leader in clinical trials for decades and has a strong track record working with the FDA. Furthermore, Syneos Health brings a regulatory affairs team that has years of experience with neurological drugs and intranasal devices. We believe that intranasal drug delivery in the acute phase following concussion is critical to dampening brain inflammation and improving patient outcomes," stated Michael Redmond, CEO of Odyssey Health.

    our twitterour facebook page
    Small Cap Corner

    Spotlighting Small Cap companies with solid foundations and long term potential.